Ayadi Lobna, Chaabouni Salma, Khabir Abdelmajid, Amouri Habib, Makni Saloua, Guermazi Mohamed, Frikha Mounir, Boudawara Tahya Sellami
Department of Pathology, Habib Bourguiba University Hospital, Sfax, Tunisia.
Department of Gynecology, Hedi Chaker University Hospital, Sfax, Tunisia.
World J Oncol. 2010 Jun;1(3):118-128. doi: 10.4021/wjon2010.06.213w. Epub 2010 May 19.
Ovarian cancer is the leading cause of death from gynaecological malignancies. Newer biological prognostic factors and predictors of response to therapy are needed. Our study was designed to evaluate the expression of p53, Bcl-2, Estrogen receptor (ER) and Progesterone receptor (PR) in ovarian carcinoma and to compare it with other prognostic parameters such as age, FIGO stage, size of residual tumor, histological type and grade.
This is a retrospective study conducted in the department of pathology at Sfax University Hospital. Confirmed 57 cases of ovarian carcinoma were reviewed in the period between January 1995 and December 2006. We used immunohistochemistry to evaluate the expression of p53, Bcl-2, ER and PR receptors and Chi-Square and Student test to correlate immunohistochemical findings with some prognostic parameters of ovarian carcinoma.
The percentage of expression of p53, Bcl-2, ER and PR was 73,7; 47,4; 35,1 and 33,3 % respectively. p53 overexpression correlated with an advanced FIGO stage (p = 0,026) and presence of ascitis (p < 10). The expression of PR was associated with an early stage (FIGO I and II), a non serous histologic type and a low tumour grade (p = 0,045; 0,010 and 0,036 respectively). No correlation was found between Bcl-2 and ER and prognostic parameters. Survival analysis revealed that Bcl-2 status, FIGO stage, presence of ascites, peritoneal cytology, and residual disease were significant predictive factors of survival.
p53 expression correlates with a worse prognosis in epithelial ovarian cancer, whereas Bcl-2 expression is related to a better outcome. For hormonal status, expression of PR is found to be an independent indicator of favourable prognosis. These results should be supported by more and larger studies.
卵巢癌是妇科恶性肿瘤致死的主要原因。需要更新的生物学预后因素及治疗反应预测指标。我们的研究旨在评估p53、Bcl-2、雌激素受体(ER)和孕激素受体(PR)在卵巢癌中的表达,并将其与其他预后参数如年龄、国际妇产科联盟(FIGO)分期、残余肿瘤大小、组织学类型和分级进行比较。
这是一项在斯法克斯大学医院病理科进行的回顾性研究。对1995年1月至2006年12月期间确诊的57例卵巢癌病例进行了回顾。我们采用免疫组织化学法评估p53、Bcl-2、ER和PR受体的表达,并使用卡方检验和学生检验将免疫组织化学结果与卵巢癌的一些预后参数进行关联。
p53、Bcl-2、ER和PR的表达百分比分别为73.7%、47.4%、35.1%和33.3%。p53过表达与FIGO晚期(p = 0.026)和腹水存在(p < 0.01)相关。PR的表达与早期(FIGO I和II期)、非浆液性组织学类型和低肿瘤分级相关(分别为p = 0.045、0.010和0.036)。未发现Bcl-2和ER与预后参数之间存在相关性。生存分析显示,Bcl-2状态、FIGO分期、腹水存在、腹膜细胞学检查和残余疾病是生存的重要预测因素。
p53表达与上皮性卵巢癌预后较差相关,而Bcl-2表达与较好的预后相关。对于激素状态,PR的表达被发现是预后良好的独立指标。这些结果应得到更多更大规模研究的支持。